共 50 条
- [21] Safety, tolerability, pharmacokinetics, and antitumor activity of SHR-A1811 in HER2-expressing/mutated advanced solid tumors: A global phase 1, multi-center, first-in-human studyCANCER RESEARCH, 2023, 83 (08)Yao, HeruiYan, MinTong, ZhongshengWu, XinhongRyu, Min-HeeKim, Jee HyunPark, JohnZhong, YahuaHan, WeiqingLiu, CaigangVoskoboynik, MarkQin, QunZhang, JianBarve, MinalAcuna-Villaorduna, AnaGanju, VinodIm, Seock-AhYe, ChangshengYin, YongmeiRoy, Amitesh C.Bai, Li-YuanLin, Yung-ChangYen, Chia-JuiLi, HuiChung, Ki YoungGu, ShanzhiQian, JunTeng, YueeChen, YidingShen, YuZhao, KaijingRong, ShangyiZhu, XiaoyuSong, Erwei
- [22] Pyrotinib in HER2-Mutant Advanced Lung Adenocarcinoma After Platinum-Based Chemotherapy: A Multicenter, Open-Label, Single-Arm, Phase II StudyJOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (24) : 2753 - +Zhou, CaicunLi, XingyaWang, QimingGao, GuanghuiZhang, YipingChen, JianhuaShu, YongqianHu, YanpingFan, YunFang, JianChen, GongyanZhao, JunHe, JianxingWu, FengyingZou, JianjunZhu, XiaoyuLin, Xiang
- [23] Safety and efficacy of atezolizumab in Chinese patients with previously treated locally advanced or metastatic non-small cell lung cancer: An open-label, single-arm, multicenter studyLUNG CANCER, 2023, 183Xu, YanjunHuang, ZhiyuChang, JianhuaYu, YanLiu, ChunlingLi, JuanZhao, JingLv, DongqingSun, SiZhang, QiannanZhou, YiXu, JiahuiFan, Yun
- [24] A multicenter, open-label, phase II trial evaluating the safety and efficacy of folate receptor alpha (FRa) antibody-drug conjugate (ADC) farletuzumab ecteribulin (FZEC*) in patients with previously treated, metastatic non-small cell lung cancer (NSCLC) adenocarcinoma (AC)JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (04) : S83 - S84Planchard, D.Paz-Ares, L.Spira, A.Felip, E.McCune, S.Cascella, T.Dennie, J.Bhagavatheeswaran, P.Dumitru, C.Borghaei, H.
- [25] Final survival and safety results from a multicenter, open-label, phase IIIb trial of erlotinib in patients with advanced non-small cell lung cancer.JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 406S - 406SO'Neill, V.Hainsworth, J.Spigel, D.Bloss, J. D.
- [26] Open-label, single arm, multicenter, phase 11 study on the efficacy and safety of cetuximab in combination with cisplatin and gemcitabine as 1st-line therapy in patients with advanced non-small cell lung cancerJOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S290 - S291Barata, FernandoParente, BarbaraTeixeira, EncarnacaoCosta, AgostinhoFernandes, AnaPimentel, Francisco L.Andrade, Sofia
- [27] Erlotinib in progressive pretreated advanced non-small cell lung cancer (NSCLC): Results of a phase II open-label trialANNALS OF ONCOLOGY, 2007, 18 : 26 - 26Piantedosi, F., VGilli, M.Caputo, F.Casale, B.Bianco, A.Dericoloso, A.Pontillo, A.Crispino, C.Giuliarini, G.Hengheller, M.Chianca, P.
- [28] Treatment of recurrent or progressive brain metastases with patupilone in patients with non-small cell lung cancer (NSCLC): results of a multicenter, open-label phase II studyEJC SUPPLEMENTS, 2007, 5 (04): : 372 - 372Abrey, L.Johri, A.Wen, P. Y.Govindan, R.Reimers, H. J.Robins, H. I.de Bedout, S.Hennan, L.Ko, J. L.Rigas, J. R.
- [29] Phase 1/2 study of the safety and clinical activity of durvalumab in patients with non-small cell lung cancer (NSCLC)ANNALS OF ONCOLOGY, 2016, 27Antonia, S. J.Brahmer, J. R.Khleif, S.Balmanoukian, A. S.Ou, S-H. I.Gutierrez, M.Kim, D-W.Kim, S-W.Ahn, M-J.Leach, J.Jamal, R.Jaeger, D.Jerusalem, G.Jin, X.Gupta, A.Antal, J.Segal, N. H.
- [30] AK112, a novel PD-1/VEGF bispecific antibody, in combination with chemotherapy in patients with advanced non-small cell lung cancer (NSCLC): an open-label, multicenter, phase II trialECLINICALMEDICINE, 2023, 62Zhao, YuanyuanChen, GangChen, JianhuaZhuang, LiDu, YingyingYu, QitaoZhuang, WuZhao, YanqiuZhou, MingZhang, WeidongZhang, YuWan, YixinLi, WentingSong, WeifengWang, Zhongmin MaxwellLi, BaiyongXia, MichelleYang, YunpengFang, WenfengHuang, YanZhang, Li